Zeta OLIG2 Antibody. Zeta’s recombinant rabbit antibody recognizes OLIG2, a basic helix-loop-helix transcription factor involved in oligodendroglial specification and with an important role in development. OLIG2 is a marker of oligodendrocyte progenitor cells and essential for selection of motor neuron and oligodendrocyte fates and choice of neural progenitors to either proliferate or differentiate.
OLIG2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for OLIG2, expression is very weak in terms of both percentage of labeled cells and intensity. No OLIG2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub ependymomas, medulloblastomas, and nonneuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and hemangioblastomas. Compared to the strong staining seen in glioma samples, a weak OLIG2expression is observed in non-tumoral brain tissue (gliosis).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.